Brain structural alterations and cognitive dysfunction in lung cancer patients without brain metastasis
“This study explored the relationship between cognitive function and brain structure in lung cancer (LCs) patients without brain metastases and healthy controls (HCs). A cohort of 75 chemotherapy-naive LCs without brain metastases and 29 age-, sex-, and education-matched HCs underwent cognitive assessments and structural MRI. The MRI focused on cortical thickness, surface area, and volume of subcortical structures.”
Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma
“Although EGFR tyrosine kinase inhibitors (EGFR-TKIs) are effective for EGFR-mutant lung adenocarcinoma (LUAD), resistance inevitably develops through diverse mechanisms, including secondary genetic mutations, amplifications and as-yet undefined processes.”
Final Overall Survival Data: Amivantamab-vmjw Plus Lazertinib vs Osimertinib in EGFR-Mutated Non–Small Cell Lung Cancer
““The survival curve tells a clear story. Amivantamab plus lazertinib helps patients live longer, and the benefit keeps growing over time,” said trial investigator Nicolas Girard, MD, PhD, Head of Medical Oncology, Institut Curie, and Professor of Thoracic Oncology and Respiratory Medicine, Paris-Saclay University, France. “We see the gap between the survival curves continue to widen, which is exactly what we want to see in lung cancer treatment to improve outcomes for patients. These results reinforce that we are entering a new era for EGFR-mutated non–small cell lung cancer.””
On the move: giant trucks to deliver lung cancer screening to remote communities
“A cardiologist’s vision to bring diagnostic cardiac services to the Queensland bush led to the creation of ‘Heart of Australia’ – a fleet of purpose-built clinics on wheels that will now be boosted to take the National Lung Cancer Screening Program to Australians living in rural, remote and First Nations communities.”
Biomarker Testing Remains Crucial for Young Patients With Lung Cancer
“Key Takeaways: Young lung cancer patients have a higher incidence of targetable biomarkers, necessitating comprehensive testing for ALK fusions and EGFR mutations. Repeat biomarker testing is essential when resistance to targeted therapies occurs, revealing new mutations and guiding treatment adjustments.”
A phenome-wide Mendelian randomization analysis reveals the genetical associations of myocardial infarction, angina pectoris and Alzheimer’s disease with lung cancer
“Lung cancer is a complex disease with varying subtypes. The genetic architectures and risk factors that are similar or distinct among these subtypes remain unclear. In this work, Genome-wide association studies (GWAS) conducted by the International Lung Cancer Consortium and transdisciplinary Research in Cancer of the Lung were utilized to illustrate the genetic landscapes of different subtypes of lung cancer.”
Fred Hutch study finds genetic driver of drug resistance in small cell lung cancer
“Researchers use CRISPR-Cas9 gene-editing tool on tumor cells grown in mice to better model how tumors that initially respond to chemotherapy become resistant.”
Pregnancy-specific glycoproteins linked to poor outcomes for women with lung cancer
“Key takeaways: Female patients whose lung cancer had pregnancy-specific glycoprotein expression had worse survival outcomes. A treatment strategy that targets these proteins could improve outcomes.”
Immunotherapy in lung cancer brain metastases
“Brain metastases (BM) occur frequently in lung cancer, particularly in non-small cell lung cancer (NSCLC) patients and remain a significant cause of morbidity and mortality. Standard therapies have limited efficacy due to poor crossing of the blood-brain barrier and the distinct features between BM and the primary tumor. This review explores the immune landscape of brain metastatic disease, emerging immunotherapeutic strategies, and promising biomarkers in NSCLC patients.”
Study introduces heart-sparing technique in lung cancer radiotherapy
“A new study presented at ESTRO 2025 introduces the RAPID-RT study, which uses an innovative rapid-learning approach to evaluate the impact of treatment modifications in radiotherapy.”
Suppressing key enzymes could improve lung cancer treatment outcomes
“Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer, according to a new Yale study.”
Cigna denies life-saving operation to man battling stage 4 cancer
“A man fighting for his life as he battles stage 4 cancer is asking for donations after his health insurance denied him a life-saving lung transplant. Deron Wells, 59, is battling advanced lung cancer and his doctors have approved him for a double transplant, a procedure that his loved ones have described as his “only path to survival.” However, Cigna Healthcare, his health insurer, has refused to authorize the transplant and the emergency medical transport needed to get him to the hospital for the operation.”
BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test
“Vancouver, British Columbia–(Newsfile Corp. – May 12, 2025) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) (“BioMark”), a leading developer of liquid biopsy tests for early cancer detection, today announced the publication of a pivotal study as part of the special issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular Sciences. The research, titled “Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection”, provides significant external validation for BioMark’s metabolomics and machine learning powered technology, particularly highlighting its high specificity and accuracy in detecting early-stage non-small cell lung cancer (NSCLC) and differentiating it from other non-cancerous lung conditions.”
